Systemic steroid exposure is associated with differential methylation in chronic obstructive pulmonary disease

Emily S. Wan, Weiliang Qiu, Andrea Baccarelli, Vincent J. Carey, Helene Bacherman, Stephen Israel Rennard, Alvar Agustí, Wayne H. Anderson, David A. Lomas, Dawn L. DeMeo

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Rationale: Systemic glucocorticoids are used therapeutically to treat a variety of medical conditions. Epigenetic processes such as DNA methylation may reflect exposure to glucocorticoids and may be involved in mediating the responses and side effects associated with these medications. Objectives: To test the hypothesis that differences in DNA methylation are associated with current systemic steroid use. Methods: We obtained DNA methylation data at 27,578 CpG sites in 14,475 genes throughout the genome in two large, independent cohorts: the International COPD Genetics Network (ndiscovery = 1,085) and the Boston Early Onset COPD study (nreplication = 369). Sites were tested for association with current systemic steroid use using generalized linear mixed models. Measurements and Main Results: A total of 511 sites demonstrated significant differential methylation by systemic corticosteroid use in all three of our primary models. Pyrosequencing validation confirmed robust differential methylation at CpG sites annotated to genes such as SLC22A18, LRP3, HIPK3, SCNN1A, FXYD1, IRF7, AZU1, SIT1, GPR97, ABHD16B, and RABGEF1. Functional annotation clustering demonstrated significant enrichment in intrinsic membrane components, hemostasis and coagulation, cellular ion homeostasis, leukocyte and lymphocyte activation and chemotaxis, protein transport, and responses to nutrients. Conclusions: Our analyses suggest that systemic steroid use is associated with site-specific differential methylation throughout the genome. Differentially methylated CpG sites were found in biologically plausible and previously unsuspected pathways; these genes and pathways may be relevant in the development of novel targeted therapies.

Original languageEnglish (US)
Pages (from-to)1248-1255
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume186
Issue number12
DOIs
StatePublished - Dec 15 2012

Fingerprint

DNA Methylation
Chronic Obstructive Pulmonary Disease
Methylation
Steroids
Glucocorticoids
Genetic Epigenesis
Genome
Genes
Protein Transport
Chemotaxis
Lymphocyte Activation
Hemostasis
Cluster Analysis
Linear Models
Adrenal Cortex Hormones
Leukocytes
Homeostasis
Ions
Food
Membranes

Keywords

  • Chronic obstructive pulmonary disease
  • DNA methylation
  • Glucocorticoids

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Systemic steroid exposure is associated with differential methylation in chronic obstructive pulmonary disease. / Wan, Emily S.; Qiu, Weiliang; Baccarelli, Andrea; Carey, Vincent J.; Bacherman, Helene; Rennard, Stephen Israel; Agustí, Alvar; Anderson, Wayne H.; Lomas, David A.; DeMeo, Dawn L.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 186, No. 12, 15.12.2012, p. 1248-1255.

Research output: Contribution to journalArticle

Wan, ES, Qiu, W, Baccarelli, A, Carey, VJ, Bacherman, H, Rennard, SI, Agustí, A, Anderson, WH, Lomas, DA & DeMeo, DL 2012, 'Systemic steroid exposure is associated with differential methylation in chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 12, pp. 1248-1255. https://doi.org/10.1164/rccm.201207-1280OC
Wan, Emily S. ; Qiu, Weiliang ; Baccarelli, Andrea ; Carey, Vincent J. ; Bacherman, Helene ; Rennard, Stephen Israel ; Agustí, Alvar ; Anderson, Wayne H. ; Lomas, David A. ; DeMeo, Dawn L. / Systemic steroid exposure is associated with differential methylation in chronic obstructive pulmonary disease. In: American Journal of Respiratory and Critical Care Medicine. 2012 ; Vol. 186, No. 12. pp. 1248-1255.
@article{10b3bbcb4b974e18b07bdb5d7f0526f7,
title = "Systemic steroid exposure is associated with differential methylation in chronic obstructive pulmonary disease",
abstract = "Rationale: Systemic glucocorticoids are used therapeutically to treat a variety of medical conditions. Epigenetic processes such as DNA methylation may reflect exposure to glucocorticoids and may be involved in mediating the responses and side effects associated with these medications. Objectives: To test the hypothesis that differences in DNA methylation are associated with current systemic steroid use. Methods: We obtained DNA methylation data at 27,578 CpG sites in 14,475 genes throughout the genome in two large, independent cohorts: the International COPD Genetics Network (ndiscovery = 1,085) and the Boston Early Onset COPD study (nreplication = 369). Sites were tested for association with current systemic steroid use using generalized linear mixed models. Measurements and Main Results: A total of 511 sites demonstrated significant differential methylation by systemic corticosteroid use in all three of our primary models. Pyrosequencing validation confirmed robust differential methylation at CpG sites annotated to genes such as SLC22A18, LRP3, HIPK3, SCNN1A, FXYD1, IRF7, AZU1, SIT1, GPR97, ABHD16B, and RABGEF1. Functional annotation clustering demonstrated significant enrichment in intrinsic membrane components, hemostasis and coagulation, cellular ion homeostasis, leukocyte and lymphocyte activation and chemotaxis, protein transport, and responses to nutrients. Conclusions: Our analyses suggest that systemic steroid use is associated with site-specific differential methylation throughout the genome. Differentially methylated CpG sites were found in biologically plausible and previously unsuspected pathways; these genes and pathways may be relevant in the development of novel targeted therapies.",
keywords = "Chronic obstructive pulmonary disease, DNA methylation, Glucocorticoids",
author = "Wan, {Emily S.} and Weiliang Qiu and Andrea Baccarelli and Carey, {Vincent J.} and Helene Bacherman and Rennard, {Stephen Israel} and Alvar Agust{\'i} and Anderson, {Wayne H.} and Lomas, {David A.} and DeMeo, {Dawn L.}",
year = "2012",
month = "12",
day = "15",
doi = "10.1164/rccm.201207-1280OC",
language = "English (US)",
volume = "186",
pages = "1248--1255",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "12",

}

TY - JOUR

T1 - Systemic steroid exposure is associated with differential methylation in chronic obstructive pulmonary disease

AU - Wan, Emily S.

AU - Qiu, Weiliang

AU - Baccarelli, Andrea

AU - Carey, Vincent J.

AU - Bacherman, Helene

AU - Rennard, Stephen Israel

AU - Agustí, Alvar

AU - Anderson, Wayne H.

AU - Lomas, David A.

AU - DeMeo, Dawn L.

PY - 2012/12/15

Y1 - 2012/12/15

N2 - Rationale: Systemic glucocorticoids are used therapeutically to treat a variety of medical conditions. Epigenetic processes such as DNA methylation may reflect exposure to glucocorticoids and may be involved in mediating the responses and side effects associated with these medications. Objectives: To test the hypothesis that differences in DNA methylation are associated with current systemic steroid use. Methods: We obtained DNA methylation data at 27,578 CpG sites in 14,475 genes throughout the genome in two large, independent cohorts: the International COPD Genetics Network (ndiscovery = 1,085) and the Boston Early Onset COPD study (nreplication = 369). Sites were tested for association with current systemic steroid use using generalized linear mixed models. Measurements and Main Results: A total of 511 sites demonstrated significant differential methylation by systemic corticosteroid use in all three of our primary models. Pyrosequencing validation confirmed robust differential methylation at CpG sites annotated to genes such as SLC22A18, LRP3, HIPK3, SCNN1A, FXYD1, IRF7, AZU1, SIT1, GPR97, ABHD16B, and RABGEF1. Functional annotation clustering demonstrated significant enrichment in intrinsic membrane components, hemostasis and coagulation, cellular ion homeostasis, leukocyte and lymphocyte activation and chemotaxis, protein transport, and responses to nutrients. Conclusions: Our analyses suggest that systemic steroid use is associated with site-specific differential methylation throughout the genome. Differentially methylated CpG sites were found in biologically plausible and previously unsuspected pathways; these genes and pathways may be relevant in the development of novel targeted therapies.

AB - Rationale: Systemic glucocorticoids are used therapeutically to treat a variety of medical conditions. Epigenetic processes such as DNA methylation may reflect exposure to glucocorticoids and may be involved in mediating the responses and side effects associated with these medications. Objectives: To test the hypothesis that differences in DNA methylation are associated with current systemic steroid use. Methods: We obtained DNA methylation data at 27,578 CpG sites in 14,475 genes throughout the genome in two large, independent cohorts: the International COPD Genetics Network (ndiscovery = 1,085) and the Boston Early Onset COPD study (nreplication = 369). Sites were tested for association with current systemic steroid use using generalized linear mixed models. Measurements and Main Results: A total of 511 sites demonstrated significant differential methylation by systemic corticosteroid use in all three of our primary models. Pyrosequencing validation confirmed robust differential methylation at CpG sites annotated to genes such as SLC22A18, LRP3, HIPK3, SCNN1A, FXYD1, IRF7, AZU1, SIT1, GPR97, ABHD16B, and RABGEF1. Functional annotation clustering demonstrated significant enrichment in intrinsic membrane components, hemostasis and coagulation, cellular ion homeostasis, leukocyte and lymphocyte activation and chemotaxis, protein transport, and responses to nutrients. Conclusions: Our analyses suggest that systemic steroid use is associated with site-specific differential methylation throughout the genome. Differentially methylated CpG sites were found in biologically plausible and previously unsuspected pathways; these genes and pathways may be relevant in the development of novel targeted therapies.

KW - Chronic obstructive pulmonary disease

KW - DNA methylation

KW - Glucocorticoids

UR - http://www.scopus.com/inward/record.url?scp=84871763019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871763019&partnerID=8YFLogxK

U2 - 10.1164/rccm.201207-1280OC

DO - 10.1164/rccm.201207-1280OC

M3 - Article

VL - 186

SP - 1248

EP - 1255

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 12

ER -